NCT01570829 is a Phase 3 clinical trial of Dietressa in Obesity, sponsored by Materia Medica Holding.

Who is sponsoring NCT01570829?

NCT01570829 is sponsored by Materia Medica Holding.

What drugs are being tested in NCT01570829?

Interventions in NCT01570829: Dietressa, Placebo.

Is NCT01570829 still recruiting?

NCT01570829 is currently completed. Last updated 25 August 2021.

Are results published for NCT01570829?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-08-25 · How we verify

NCT01570829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients

Completed Phase 3 Results posted Last updated 25 August 2021

What this trial tests

Phase 3 trial testing Dietressa in Obesity in 331 participants. Completed in 1 June 2013.

Timeline

1 December 2011

Primary endpoint
1 June 2013

1 June 2013

Quick facts

Lead sponsor	Materia Medica Holding
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	331
Start date	1 December 2011
Primary completion	1 June 2013
Estimated completion	1 June 2013
Sites	17 locations across Russia

Drugs / interventions tested

Dietressa — full drug profile →
Placebo

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Materia Medica Holding — full company profile →

Who can join

Adults 18 to 65, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Patients With at Least 5% Weight Loss.
Time frame: 24 weeks
Based on medical records.
Average Absolute Weight Change
Time frame: On baseline and after 24 weeks
Based on medical records.
Average Relative Weight Change
Time frame: On baseline and after 24 weeks
Based on medical records.

Sponsor's own description

* To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2). * To assess clinical efficacy of Dietressa in the dose of 6 tablets daily after 24 weeks of therapy in reducing body weight in obese patients (BMI 35,0-39,9 kg/m2).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Materia Medica Holding trials

Trials by the same sponsor.

NCT07171099 — Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children · Phase 3 · recruiting
NCT06901297 — The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients · Phase 3 · recruiting
NCT06715891 — Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years · Phase 3 · recruiting
NCT06263881 — Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia · Phase 3 · completed
NCT06284265 — Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01570829 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Materia Medica Holding
Last refreshed: 25 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01570829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing